Thirteen IPOs raised a combined $4.4 billion in February, joined by two direct listings. Deal flow started off strong but stumbled mid-month as concerns around AI disruption sparked a sell-off in tech stocks and recent listings, and heightened volatility led to ...read more
SpyGlass Pharma, a Phase 3 biotech developing implanted drug-devices for chronic eye conditions, raised $150 million by offering 9.4 million shares at $16, the midpoint of the range of $15 to $17. SpyGlass Pharma is a late-stage biopharmaceutical company...read more
SpyGlass Pharma, a Phase 3 biotech developing implants to treat chronic eye conditions, announced terms for its IPO on Thursday. The Aliso Viejo, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the ...read more
SpyGlass Pharma, a phase 3 biotech developing implants to treat chronic eye conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering. SpyGlass Pharma is a late-stage biopharmaceutical company focused on chronic eye...read more
Renaissance Capital's February IPO Market Update
Thirteen IPOs raised a combined $4.4 billion in February, joined by two direct listings. Deal flow started off strong but stumbled mid-month as concerns around AI disruption sparked a sell-off in tech stocks and recent listings, and heightened volatility led to ...read more
Chronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint
SpyGlass Pharma, a Phase 3 biotech developing implanted drug-devices for chronic eye conditions, raised $150 million by offering 9.4 million shares at $16, the midpoint of the range of $15 to $17. SpyGlass Pharma is a late-stage biopharmaceutical company...read more
Chronic eye condition biotech SpyGlass Pharma sets terms for $150 million IPO
SpyGlass Pharma, a Phase 3 biotech developing implants to treat chronic eye conditions, announced terms for its IPO on Thursday. The Aliso Viejo, CA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17. At the ...read more
Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO
SpyGlass Pharma, a phase 3 biotech developing implants to treat chronic eye conditions, filed on Friday with the SEC to raise up to $100 million in an initial public offering. SpyGlass Pharma is a late-stage biopharmaceutical company focused on chronic eye...read more